Can a simple inhalation prevent oxygen drops in obese patients during lung surgery?
NCT ID NCT04583046
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether inhaling iloprost, a drug that widens blood vessels in the lungs, can improve oxygen levels in obese patients during one-lung ventilation for lung surgery. 78 participants were randomly assigned to receive either iloprost or a saltwater placebo. The researchers measured oxygen in the blood and other breathing parameters to see if iloprost reduces the risk of dangerously low oxygen.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- iloprost inhalation
- What this could lead to
- If successful, this could point toward a way to prevent dangerously low oxygen levels in obese patients during lung surgery.
- What could go wrong
- This is a small, early-stage study focused on short-term oxygen measurements, not long-term outcomes. The results may not apply to all patients or surgeries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
78 people
The number who actually took part.
- Started
-
Nov 2020
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. scheduled for VATS lobectomy 2. 40 \< age \< 80 3. American Society of Anaesthesiologists(ASA) physical status classification I\~III 4. BMI \> 30 kg /m2 Exclusion Criteria: 1. American Society of Anaesthesiologists(ASA) physical status classification IV or more 2. NYHA class III\~IV 3. Severe obstructive lung disease and/or restrictive lung disease patients 4. patients with end-organ diseases (i.e. heart failure, respiratory failure, hepatic failure, renal failure) 5. arrhythmia 6. pregnant women 7. pulmonary edema or pulmonary arterial hypertension 8. cerebrovascular disease 9. unstable angina or myocardial infarction within 6 months 10. patients with allergic reaction at iloprost
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer (including metastatic cancer) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Viruses that kill bacteria: a new weapon against superbugs?
- Can tilting a Patient's body toward the infection help them breathe free sooner?
- Electric pulses vs. pelvic tumors: a new hope when surgery fails?
- Breathing in xenon: a new way to see lung problems?
- New combo device aims to keep patients breathing safely during lung scope
- New drug combo aims to prevent oxygen drops during lung scope procedures